Teva reports Q1 EPS 52c, consensus 46c

Reports Q1 revenue $3.891B, consensus $3.99B. Richard Francis, Teva‘s (TEVA) President and CEO, said, “Teva had a solid start to the year, with its ninth consecutive quarter of revenue growth, delivering global revenues of $3.9 billion, an increase of 5% in local currency terms compared to the first quarter of 2024. Our key innovative growth drivers continue to show strong momentum, collectively generating revenues of $589 million while each growing more than 25% year over year. We also achieved solid generics performance across all regions with biosimilars rounding out the portfolio.”